2019
“Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer
Wang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer. Journal Of Geriatric Oncology 2019, 11: 850-859. PMID: 31899199, PMCID: PMC7263974, DOI: 10.1016/j.jgo.2019.12.010.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedBreast NeoplasmsFemaleHumansLife ExpectancyMastectomy, SegmentalMiddle AgedModels, StatisticalNeoplasm Recurrence, LocalNeoplasm StagingRisk AssessmentConceptsEarly-stage breast cancerRisk calculatorLocal recurrenceBreast cancerOlder womenTumor characteristicsBreast cancer-specific outcomesReceipt of radiotherapyCancer-specific outcomesEarly breast cancerIndividual patient's riskBenefits of radiotherapyAdvisory CommitteeLife expectancyOnline risk calculatorLong-term survivalShared decision makingBenefit of RTOlder adult womenRadiotherapy statusCause mortalityOverall survivalRecurrence reductionFunctional statusPatient riskA Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management
Kunst NR, Alarid-Escudero F, Paltiel AD, Wang SY. A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. Value In Health 2019, 22: 1102-1110. PMID: 31563252, PMCID: PMC7343670, DOI: 10.1016/j.jval.2019.05.004.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerObservational studyBreast cancerLow-risk early-stage breast cancerHormone receptor-positive early-stage breast cancerPredictive valueLow-risk womenProspective observational studyHigh-risk womenRetrospective observational studyBreast cancer managementQuality-adjusted life yearsCost-effectiveness findingsTraditional risk predictionAdjuvant chemotherapyChemotherapy useAlternative study designsOncotype DXCancer managementClinical utilityCurrent evidenceInsufficient evidenceLife yearsRoutine useStudy designIncorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal Of The National Comprehensive Cancer Network 2019, 17: 39-46. PMID: 30659128, DOI: 10.6004/jnccn.2018.7077.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClinical Decision-MakingConnecticutCost-Benefit AnalysisDecision Support TechniquesFemaleGene Expression ProfilingGenetic TestingHumansMarkov ChainsMastectomyMiddle AgedModels, StatisticalNeoplasm Recurrence, LocalPrevalencePrognosisQuality-Adjusted Life YearsRisk AssessmentConceptsIncremental cost-effectiveness ratioClinical risk groupsQuality-adjusted life yearsHigh-risk groupLow-risk groupOncotype DXRisk groupsBreast cancerLymph node-negative breast cancerDifferent clinical risk groupsLow-risk breast cancerNode-negative breast cancerIntermediate-risk groupRecurrence score (RS) distributionConnecticut Tumor RegistryER-positive diseaseUS payer perspectivePopulation-based dataCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness analysisODX resultsClinical characteristicsMost patientsPatient age
2014
Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer
Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP. Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. Journal Of The National Cancer Institute 2014, 106: dju008. PMID: 24598714, PMCID: PMC3982782, DOI: 10.1093/jnci/dju008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrachytherapyBreast NeoplasmsComorbidityCost-Benefit AnalysisFemaleHealth ExpendituresHumansLife ExpectancyMedicareNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeQuality-Adjusted Life YearsRadiotherapy, Intensity-ModulatedRisk AssessmentRisk FactorsSampling StudiesSEER ProgramUnited StatesConceptsExternal beam radiation therapyIncremental cost-effectiveness ratioQuality-adjusted life yearsBreast cancerOlder womenRadiation therapyEnd Results-Medicare databaseRisk breast cancerBeam radiation therapyCost-effectiveness ratioNewer radiation therapy modalitiesQuality of lifeRadiation therapy modalitiesLocal recurrenceTrial criteriaRT modalityTherapy modalitiesLife yearsCancerIncremental costTherapyWomenBaseline stateNew modality
2012
Network Meta-analysis of Margin Threshold for Women With Ductal Carcinoma In Situ
Wang SY, Chu H, Shamliyan T, Jalal H, Kuntz KM, Kane RL, Virnig BA. Network Meta-analysis of Margin Threshold for Women With Ductal Carcinoma In Situ. Journal Of The National Cancer Institute 2012, 104: 507-516. PMID: 22440677, PMCID: PMC3916966, DOI: 10.1093/jnci/djs142.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceBreast-conserving surgeryRisk of IBTRNegative marginsPositive marginsDuctal carcinomaOdds ratioBreast tumor recurrenceNegative surgical marginsNetwork Meta-AnalysisMixed treatment comparisonMargin thresholdIBTR eventsDCIS patientsMargin statusSurgical marginsTumor recurrenceMeta-regression techniquesReduced riskLower riskPatientsPubMed databaseCosmetic constraintsMeta-AnalysisRadiotherapy
2011
Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis
Wang SY, Shamliyan T, Virnig BA, Kane R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Research And Treatment 2011, 127: 1-14. PMID: 21327465, DOI: 10.1007/s10549-011-1387-4.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastFemaleHumansNeoplasm Recurrence, LocalNeoplasm StagingPrognosisReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneConceptsIpsilateral breast tumor recurrenceHER2/neu receptorTumor characteristicsLocal recurrenceDuctal carcinomaTumor sizeTumor gradeLow-risk DCIS patientsNeu receptorManagement of DCISBreast tumor recurrenceHigh-quality evidenceCourse of treatmentDCIS patientsAggressive treatmentPrognostic factorsSurgical marginsTumor recurrenceSubgroup analysisObservational studyMethod of detectionEligible articlesSystematic reviewRecurrenceDCIS
2010
The Impact of Surgery, Radiation, and Systemic Treatment on Outcomes in Patients With Ductal Carcinoma In Situ
Kane RL, Virnig BA, Shamliyan T, Wang SY, Tuttle TM, Wilt TJ. The Impact of Surgery, Radiation, and Systemic Treatment on Outcomes in Patients With Ductal Carcinoma In Situ. JNCI Monographs 2010, 2010: 130-133. PMID: 20956816, PMCID: PMC5161061, DOI: 10.1093/jncimonographs/lgq022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingChemotherapy, AdjuvantCombined Modality TherapyDisease ProgressionFemaleHumansIncidenceMastectomyMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrognosisRadiotherapy, AdjuvantRandomized Controlled Trials as TopicTamoxifenTreatment OutcomeConceptsBreast-conserving surgeryDuctal carcinomaInvasive carcinomaWhole breast radiation therapyImpact of surgeryTerms of recurrenceInvasive recurrenceRecurrent DCISDCIS recurrenceSystemic treatmentObservational studyRadiation therapyEquivalent outcomesCarcinomaMastectomyRecurrenceDCISSurgeryTamoxifenLower ratesOutcomesWomenLumpectomyPatientsMEDLINEAssociation Between Patient and Tumor Characteristics With Clinical Outcomes in Women With Ductal Carcinoma In Situ
Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL. Association Between Patient and Tumor Characteristics With Clinical Outcomes in Women With Ductal Carcinoma In Situ. JNCI Monographs 2010, 2010: 121-129. PMID: 20956815, PMCID: PMC5161074, DOI: 10.1093/jncimonographs/lgq034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBody Mass IndexBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingFemaleGonadal Steroid HormonesHumansMammographyMenopauseNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPrognosisRacial GroupsRandomized Controlled Trials as TopicReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRiskSocioeconomic FactorsTreatment OutcomeTumor BurdenConceptsDuctal carcinomaClinical outcomesRecurrent cancerTumor characteristicsWorse outcomesNegative estrogen receptor statusAdvanced recurrent cancerPositive surgical marginsEstrogen receptor statusLarger tumor sizeHigh-risk categoryComposite prognostic indicesReceptor statusSurgical marginsPrognostic indexTumor sizeComedo necrosisPathological gradingClinical trialsObservational studyHigh riskHER2 receptorSynthesis of evidenceHigh mortalityYoung womenIncorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis
Wang SY, Kuntz K, Tuttle T, Kane R. Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. Breast Cancer Research And Treatment 2010, 124: 393-402. PMID: 20848183, DOI: 10.1007/s10549-010-1166-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingDecision Support TechniquesFemaleHumansMarkov ChainsMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPatient PreferencePatient SelectionQuality-Adjusted Life YearsRadiotherapy, AdjuvantRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBreast-conserving surgeryQuality-adjusted life yearsRadiation therapyMargin statusDuctal carcinomaRT side effectsDecision-analytic Markov modelOne-way sensitivity analysesImportance of patientsProbabilistic sensitivity analysesDCIS treatmentInvasive recurrenceSalvage mastectomyOptimal treatmentHypothetical cohortTreatment decisionsLifetime horizonSide effectsLife yearsDCISPatientsWomenCarcinomaTreatment